Poland· PL-100481044
Imjudo
A tremelimumab product containing tremelimumabum, registered in Poland by AstraZeneca AB. The same ATC class is registered in 16 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tremelimumab is registered in 16 of 19 countries.
Countries holding a registration under ATC L01FX20 (tremelimumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Tremelimumab · ATC L01FX20
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tremelimumab costs, country by country.
Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tremelimumab · price per daily dose (10.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$779.98
The record
At a glance
URPL (Poland)- Active substance
- Tremelimumabum
- Manufacturer
- AstraZeneca AB
- Country
- Poland (PL)
- ATC code
- L01FX20
- ATC class
- Tremelimumab
- Defined daily dose
- 10.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05000456037105
- gtin05000456037129
- gtin05000456037266
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tremelimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumImjudo 20 mg/mlAstraZeneca
- CzechiaIMJUDOAstraZeneca AB, Södertälje
- FinlandIMJUDOAstraZeneca AB
- SwedenIMJUDO 20 mg/ml Koncentrat till infusionsvätska, lösningAstraZeneca AB
- IrelandIMJUDO 20 mg/ml concentrate for solution for infusionAstraZeneca AB
- IcelandImjudoAstraZeneca AB*
- NorwayImjudoAstraZeneca AB
- United StatesIMJUDOAstraZeneca Pharmaceuticals LP
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imjudo
- Liechtenstein · Imjudo
- Norway · Imjudo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4b5a44ca-ee04-46be-b20a-f5b300d68e70 GET /v1/drugs/4b5a44ca-ee04-46be-b20a-f5b300d68e70?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "20 mg/ml",
"packaging": "05000456037105 ¦ Rpz ¦ EU/1/22/1713/001 ¦ 149277\n1 fiol. 1,25 ml\n¦ UR/Z/4c/159/23 - 05000456037129\n05000456037266 ¦ Rpz ¦ EU/1/22/1713/002 ¦ 149278\n1 fiol. 15 ml",
"substance": "Tremelimumabum 20 mg/ml",
"common_name": "Tremelimumabum",
"pl_product_id": "100481044",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about tremelimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.